Citations

Clear

3942 citation(s) found for "To, Van".

Legumain is activated in macrophages during pancreatitis
Edgington‐Mitchell, Laura E. , Wartmann, Thomas , Martinez, Alicia K. Fleming , Gocheva, Vasilena, Linden, Wouter A. van der, Withana, Nimali P., Aurelio, Luigi, Edgington-Mitchell, Daniel , Lieu, TinaMarie , Parker, Belinda S. , Graham, Bim , Reinheckel, Thomas , Furness, John B. , Joyce, Johanna A. , Störz, Peter , Halangk, Walter, Bogyo, Matthew , Bunnett, Nigel W. , Fleming, Alicia K, Verdoes, Martijn

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | August 11, 2016 | Volume: 311 | Issue: 3 | Pages: G548-G560

10.1152/ajpgi.00047.2016 | PMID 27514475 Get It

Pancreatitis is an inflammatory disease of the pancreas characterized by dysregulated activity of digestive enzymes, necrosis, immune infiltration, and pain. Repeated incidence of pancreatitis is an important risk factor for pancreatic cancer. Legumain, a lysosomal cysteine protease, has been linked to inflammatory diseases such as atherosclerosis, stroke, and cancer. Until now, legumain activation has not been studied during pancreatitis. We used a fluorescently quenched activity-based probe to assess legumain activation during caerulein-induced pancreatitis in mice. We detected activated legumain by ex vivo imaging, confocal microscopy, and gel electrophoresis. Compared with healthy controls, legumain activity in the pancreas of caerulein-treated mice was increased in a time-dependent manner. Legumain was localized to CD68+ macrophages and was not active in pancreatic acinar cells. Using a small-molecule inhibitor of legumain, we found that this protease is not essential for the initiation of pancreatitis. However, it may serve as a biomarker of disease, since patients with chronic pancreatitis show strongly increased legumain expression in macrophages. Moreover, the occurrence of legumain-expressing macrophages in regions of acinar-to-ductal metaplasia suggests that this protease may influence reprogramming events that lead to inflammation-induced pancreatic cancer.
Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts
Kramer, Nicholas J. , Carlomagno, Yari , Zhang, Yong‐Jie , Almeida, Sandra , Cook, Casey , Prudencio, Mercedes , Blitterswijk, Marka van , Belzil, Véronique , Couthouis, Julien , Paul, Joseph W. , Goodman, Lindsey D. , Daughrity, Lillian M. , Chew, Jeannie , Garrett, Aliesha, Pregent, Luc , Jansen‐West, Karen , Tabassian, Lilia J., Rademakers, Rosa , Graff‐Radford, Neill R. , Josephs, Keith A. , Parisi, Joseph E., Petersen, Ronald C. , Deng, Ning , Feng, Yanan , Cheng, Tzu-Hao, Cohen, Stanley N. , Link, Christopher D. , Gao, Fen‐Biao , Petrucelli, Leonard , Gitler, Aaron D. , O’Raw, Aliesha D. , Cook, Casey N, Gendron, Tania F. , van Blitterswijk, Marka, Daughrity, Lillian, Jansen-West, Karen, Boylan, Kevin, Boylan, Khrista , Knopman, David S. , Boeve, Bradley F. , Dickson, Dennis W. , Bonini, Nancy M. , Zhang, Yong-Jie , Prudencio, Mercedes , O'Raw, Aliesha , van Blitterswijk, Marka , Gitler, Aaron D

Mayo Clinic

Science | August 11, 2016 | Volume: 353 | Issue: 6300 | Pages: 708-712

10.1126/science.aaf7791 | PMID 27516603 Get It

Targeting three defects with one strategy The neurodegenerative diseases amyotrophic lateral sclerosis and frontotemporal dementia are most commonly caused by a mutation in the C9orf72 gene. The mutation is an expanded hexanucleotide repeat in a noncoding region. The expanded repeat produces sense and antisense RNA transcripts, which accumulate in patient cells and appear to sequester RNA-binding proteins. The sense and antisense transcripts are also translated into dipeptide repeat proteins, which are aggregation-prone and accumulate in the brain and spinal cord. Last, loss of function from reduced expression of C9orf72 in neurons and glia could contribute to the disease. Kramer et al. targeted both sense and antisense repeats by blocking a single gene called SPT4 , which mitigated degeneration in human cells by reducing all three types of pathologies. Science , this issue p. 708
Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling
Carpio, Lomeli R., Bradley, Elizabeth W. , Weivoda, Megan , Poston, Daniel , Dudakovic, Amel , Xu, Ming , Tchkonia, Tamar , Kirkland, James L. , Wijnen, André J. van , Oursler, Merry Jo, Shull, Lomeli C. , Weivoda, Megan M, Poston, Daniel D, van Wijnen, Andre J, McGee‐Lawrence, Meghan E. , Westendorf, Jennifer J. , van Wijnen, Andre J , Bradley, Elizabeth W , Xu, Ming , Tchkonia, T

Mayo Clinic

Science Signaling | August 9, 2016 | Volume: 9 | Issue: 440 | Pages: No page available

10.1126/scisignal.aaf3273 | PMID 27507649 Get It

Histone deacetylase 3 prevents chondrocytes from producing inflammatory mediators that prevent bone development.
Contemporary analysis of the intraoperative and perioperative complications of neurosurgical procedures performed in the sitting position
Mallory, Grant W., Abcejo, Arnoley S., Pasternak, Jeffrey J., Atkinson, John L. D., Meyer, Fredric B. , Marsh, W. Richard , Link, Michael J. , Perkins, William J., Pasternak, Jeffrey, Perkins, William, Himes, Benjamin , Clarke, Michelle J. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurosurgery | August 5, 2016 | Volume: 127 | Issue: 1 | Pages: 182-188

10.3171/2016.5.jns152328 | PMID 27494821 Get It

OBJECTIVE Historically, performing neurosurgery with the patient in the sitting position offered advantages such as improved visualization and gravity-assisted retraction. However, this position fell out of favor at many centers due to the perceived risk of venous air embolism (VAE) and other position-related complications. Some neurosurgical centers continue to perform sitting-position cases in select patients, often using modern monitoring techniques that may improve procedural safety. Therefore, this paper reports the risks associated with neurosurgical procedures performed in the sitting position in a modern series. METHODS The authors reviewed the anesthesia records for instances of clinically significant VAE and other complications for all neurosurgical procedures performed in the sitting position between January 1, 2000, and October 8, 2013. In addition, a prospectively maintained morbidity and mortality log of these procedures was reviewed for instances of subdural or intracerebral hemorrhage, tension pneumocephalus, and quadriplegia. Both overall and specific complication rates were calculated in relation to the specific type of procedure. RESULTS In a series of 1792 procedures, the overall complication rate related to the sitting position was 1.45%, which included clinically significant VAE, tension pneumocephalus, and subdural hemorrhage. The rate of any detected VAE was 4.7%, but the rate of VAE requiring clinical intervention was 1.06%. The risk of clinically significant VAE was highest in patients undergoing suboccipital craniotomy/craniectomy with a rate of 2.7% and an odds ratio (OR) of 2.8 relative to deep brain stimulator cases (95% confidence interval [CI] 1.2–70, p = 0.04). Sitting cervical spine cases had a comparatively lower complication rate of 0.7% and an OR of 0.28 as compared with all cranial procedures (95% CI 0.12–0.67, p < 0.01). Sitting cervical cases were further subdivided into extradural and intradural procedures. The rate of complications in intradural cases was significantly higher (OR 7.3, 95% CI 1.4–39, p = 0.02) than for extradural cases. The risk of VAE in intradural spine procedures did not differ significantly from sitting suboccipital craniotomy/craniectomy cases (OR 0.69, 95% CI 0.09–5.4, p = 0.7). Two cases (0.1%) had to be aborted intraoperatively due to complications. There were no instances of intraoperative deaths, although there was a single death within 30 days of surgery. CONCLUSIONS In this large, modern series of cases performed in the sitting position, the complication rate was low. Suboccipital craniotomy/craniectomy was associated with the highest risk of complications. When appropriately used with modern anesthesia techniques, the sitting position provides a safe means of surgical access.
Creation of a model to predict survival in patients with refractory coeliac disease using a multinational registry
Malamut, Georgia , Verbeek, Wieke H.M. , Wanrooij, Roy L.J. van , Leffler, Daniel A. , Niveloni, Sonia I., Argüelles-Grande, Carolina , Lahr, Brian D. , Zinsmeister, Alan R., Kelly, Ciarán P. , Bai, Jie , Green, P. H., Daum, S , Mulder, Chris J. , Cellier, Christophe , Rubio‐Tapia, Alberto , Murray, Joseph A. , van Wanrooij, Roy L J , Malamut, Georgia

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 3, 2016 | Volume: 44 | Issue: 7 | Pages: 704-714

10.1111/apt.13755 | PMID 27485029 Get It

SummaryBackgroundRefractory coeliac disease is a severe complication of coeliac disease with heterogeneous outcome.AimTo create a prognostic model to estimate survival of patients with refractory coeliac disease.MethodsWe evaluated predictors of 5‐year mortality using Cox proportional hazards regression on subjects from a multinational registry. Bootstrap resampling was used to internally validate the individual factors and overall model performance. The mean of the estimated regression coefficients from 400 bootstrap models was used to derive a risk score for 5‐year mortality.ResultsThe multinational cohort was composed of 232 patients diagnosed with refractory coeliac disease across seven centres (range of 11–63 cases per centre). The median age was 53 years and 150 (64%) were women. A total of 51 subjects died during a 5‐year follow‐up (cumulative 5‐year all‐cause mortality = 30%). From a multiple variable Cox proportional hazards model, the following variables were significantly associated with 5‐year mortality: age at refractory coeliac disease diagnosis (per 20 year increase, hazard ratio = 2.21; 95% confidence interval, CI: 1.38–3.55), abnormal intraepithelial lymphocytes (hazard ratio = 2.85; 95% CI: 1.22–6.62), and albumin (per 0.5 unit increase, hazard ratio = 0.72; 95% CI: 0.61–0.85). A simple weighted three‐factor risk score was created to estimate 5‐year survival.ConclusionsUsing data from a multinational registry and previously reported risk factors, we create a prognostic model to predict 5‐year mortality among patients with refractory coeliac disease. This new model may help clinicians to guide treatment and follow‐up.
Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration
Group, AOCS Study, Reid, Brett M. , Earp, Madalene A. , Chen, Y. Ann , Monteiro, Álvaro N.A. , Chen, Zhihua , Chenevix‐Trench, Georgia , Fasching, Peter A. , Beckmann, Matthias W. , Lambrechts, Diether , Vanderstichele, Adriaan , Niewenhuyse, Els Van, Vergote, Ignace , Rossing, Mary Anne, Chang‐Claude, Jenny, Moysich, Kirsten, Odunsi, Kunle , Goodman, Marc T. , Shvetsov, Yurii B. , Thompson, Pamela J., Dörk, Thilo , Bogdanova, Natalia , Pelttari, Liisa M. , Leminen, Arto, Edwards, Robert P., Ness, Roberta B., Kelley, Joseph L., Lester, Jenny, Jensen, Allan , Hildebrandt, Michelle, Liang, Dong , Lu, Karen H., Wu, Xifeng , Levine, Douglas A. , Bisogna, Maria, Berchuck, Andrew, Terry, Kathryn L. , Tworoger, Shelley S. , Cunningham, Julie M. , Winham, Stacey J. , Olson, Sara H. , Kiemeney, Lambertus A. , Massuger, Leon F.A.G. , Moffitt, Melissa , Le, Nhu, Kelemen, Linda E. , Lubiński, Jan , Wentzensen, Nicolas, Brinton, Louise A. , Lissowska, Jolanta , Yang, Hanna , Høgdall, Estrid , Høgdall, Claus , Lundvall, Lene, Song, Honglin , Campbell, Ian , Eccles, Diana , McNeish, Iain A. , Whittemore, Alice S. , McGuire, Valerie, Sieh, Weiva , Rothstein, Joseph H. , Phelan, Catherine M., Narod, Steven A., McLaughlin, John, Ziogas, Argyrios, Menon, Usha , Gayther, Simon A. , Ramus, Susan J. , Pearce, Celeste Leigh, Wu, Anna H. , Kupryjańczyk, Jolanta , Dansonka‐Mieszkowska, Agnieszka , Schildkraut, Joellen M. , Cheng, Jin Q. , Goode, Ellen L. , Sellers, Thomas A. , Lu, Karen H. , Lambrechts, Diether , Earp, Madalene, Cunningham, Julie, Permuth, Jennifer B. , Group, AOCS Study, Doherty, Jennifer A. , Wilkens, Lynne R. , Bützow, Ralf C. , Nevanlinna, Heli , Modugno, Francesmary , Heitz, Florian , Karlan, Beth Y. , Lester, Jenny, Kjær, Susanne K. , Giles, Graham G. , Cramer, Daniel W. , Poole, Elizabeth M. , Bandera, Elisa V. , Fridley, Brooke L. , Orlow, Irene , Bjørge, Line , Pejovic, Tanja B. , Cook, Linda S. , Brooks‐Wilson, Angela , Gronwald, Jacek , Wentzensen, Nicolas , Pharoah, Paul D.P. , Risch, Harvey A. , McLaughlin, John, Anton‐Culver, Hoda , Gentry‐Maharaj, Aleksandra , Pelttari, L M , Winham, Stacey J , Dörk, Thilo , Lambrechts, Diether , Kiemeney, Lambertus A , McNeish, Iain A , Ramus, Susan J , Tworoger, Shelley S , Vanderstichele, Adriaan , Jensen, Allan , Eccles, Diana , Menon, Usha , Monteiro, Alvaro N , Moysich, Kirsten , Lissowska, Jolanta , Campbell, Ian G , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Oncotarget | July 28, 2016 | Volume: 7 | Issue: 45 | Pages: 72381-72394

10.18632/oncotarget.10546 | PMID 27911851 Get It

Testing for dabigatran and rivaroxaban by clinical laboratories
Cott, Elizabeth M. Van , Smock, Kristi J. , Chen, Dong , Hsu, Peihong , Zantek, Nicole D. , Meijer, Piet , Chen, Dong , Zantek, Nicole D

Mayo Clinic

American Journal of Hematology | July 26, 2016 | Volume: 91 | Issue: 11 | Pages: No page available

10.1002/ajh.24494 | PMID 27458812 Get It

Rivaroxaban and dabigatran are among the newest anticoagulants, and measuring their concentration in patients is a new challenge for clinical laboratories. We analyzed data from the ECAT proficiency program to determine how well the assays are performing in clinical laboratories internationally. Most laboratories received a passing grade (Z score <3) for the results of their dabigatran and rivaroxaban testing. Failing Z scores were not associated with any particular method. With dabigatran, some homemade calibrators gave higher results than the commercially available calibrators. There were no significant differences among the instruments or the 5 reagents in use, but results showed inter‐laboratory variability that could have clinical significance. The 3 reagents with the lowest number of users had poor inter‐laboratory precision. Ten different anti‐Xa reagents were in use for rivaroxaban testing. One reagent gave lower results than other reagents at 100 ng/mL but not at 300 ng/mL. There were no significant differences among the different rivaroxaban calibrators or instruments. In conclusion, inter‐laboratory precision could be improved for both dabigatran and rivaroxaban assays. Homemade dabigatran calibrators differed from commercially available calibrators, and there was a statistically significant difference between some of the rivaroxaban reagents. About 10% of results received failing Z scores or passed but fell in a range that require the laboratory to investigate for bias or other inaccuracy in their method. Am. J. Hematol. 91:E464–E467, 2016. © 2016 Wiley Periodicals, Inc.
Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Buxton, Meredith , Chia, Stephen, Veer, Laura van’t, Chien, Jo, Moulder, Stacy L. , Albain, Kathy S. , Kemmer, Kathleen, Haley, Barbara , Minton, Susan, Forero, Andres , Nanda, Rita , Korde, Larissa A. , Viscuzi, Rebecca, Rugo, Hope, Schwab, Richard B. , Symmans, Fraser, Paoloni, Melissa, Lyandres, Julia, Perlmutter, Jane , Sanil, Ashish, Berry, Don, Investigators, I-SPY 2 TRIAL, DeMichele, Angela , Wallace, Anne M. , Kaplan, Henry G. , Lang, Julie E. , Yee, Douglas , Isaacs, Claudine , Boughey, Judy C. , Elias, Anthony , Hylton, Nola M. , Hogarth, Michael A. , Yau, Christina , Esserman, Laura J. , Berry, Donald A. , Investigators, I-SPY 2 TRIAL

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: CT106-CT106

10.1158/1538-7445.am2016-ct106 Get It

Abstract Background: Pathologic complete response (pCR) is an established prognostic biomarker for aggressive HER2+ breast cancer (BC). Improving pCR rates may identify new therapies that improve survival. Pertuzumab (P) has established survival benefit in the metastatic setting, and received accelerated approval in the neoadjuvant setting when combined with trastuzumab (H) and docetaxel(D) as part of a complete treatment regimen for early breast cancer. We tested its ability, when combined with standard therapy (paclitaxel, T, and H) to improve pCR (ypT0ypN0) over TH in the adaptively randomized, phase II, I-SPY 2 neoadjuvant trial. Methods: Enrolled patients (pts) had invasive BC ?2.5 cm in HER2-positive subsets. Pts were adaptively randomized to control (TH, qwk x 12) or THP (P, q3wk x 4) followed by doxorubicin/cyclophosphamide (AC) x 4 and surgery. To compare THP to TH we utilized all control pts accrued over the course of the trial, adjusting for potential differences due to time period treated, which were informed by the several other treatment arms that have been in the trial. Adaptive assignment to the experimental arms was based on current Bayesian probabilities of superiority over control. “Graduation” by signature and futility stopping were based upon Bayesian predictive probability of success in a 2-arm, N = 300 phase III randomized 1:1 trial of THP vs. TH with pCR endpoint. Results: THP met the predictive probability criterion and graduated in 3 signatures: all HER2+, HER2+/HR+, and HER2+/HR- (See Table 1). Final accrual: 44 THP and 31 TH. Safety data will be shown. Conclusions: I-SPY 2's standing platform trial efficiently evaluates agents in biomarker-defined pt subsets. THP -&gt; AC substantially improves pCR rates over standard TH -&gt; AC in all 3 HER2+ signatures, including HR+ and HR- subsets. APHINITY, a trial of adjuvant pertuzumab with a primary outcome of invasive disease-free survival, is ongoing. Table 1Signature*Estimated pCR Rate (95% probability interval)Signature*THPControl (TH)Probability THP Is Superior to ControlPredictive Probability of Success in Phase IIIHER2+54% (38%-70%)22% (5%-39%)99.8%96%HER2+/HR+44% (24%-63%)17% (0%-34%)99%91%HER2+/HR-74% (53%-95%)33% (6%-59%)99.8%98%*HR = Hormone Receptor Citation Format: Meredith Buxton, Angela M. DeMichele, Stephen Chia, Laura van't Veer, Jo Chien, Anne Wallace, Henry Kaplan, Julie Lang, Douglas Yee, Claudine Isaacs, Stacy Moulder, Kathy Albain, Judy Boughey, Kathleen Kemmer, Barbara Haley, Susan Minton, Andres Forero, Rita Nanda, Anthony Elias, Larissa Korde, Rebecca Viscuzi, Hope Rugo, Richard Schwab, Fraser Symmans, Melissa Paoloni, Nola Hylton, Michael Hogarth, Julia Lyandres, Jane Perlmutter, Ashish Sanil, Christina Yau, Laura Esserman, Don Berry, I-SPY 2 TRIAL Investigators. Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr CT106.
Abstract 3292: Manipulating osteoblast differentiation in order to inhibit protection of AML cells within the bone marrow
Sterner, Rosalie M. , Dudakovic, Amel , Kaufmann, Scott H. , Wijnen, André J. van , Kremer, Kimberly N. , Westendorf, Jennifer J. , Hedin, Karen E. , van Wijnen, Andre J , Kaufmann, Scott H

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 3292-3292

10.1158/1538-7445.am2016-3292 Get It

Abstract While standard chemotherapeutics can initially induce remission in patients with acute myelogenous leukemia (AML), patients often relapse in part due to the protective bone marrow microenvironment, which promotes the survival of AML cells. Using an in vitro cell culture model of the bone marrow, our lab recently showed that differentiating osteoblasts potently protect AML cells from apoptosis. In addition, we found that differentiating osteoblasts treated with histone deacetylase inhibitors (HDACi) fail to protect AML cells in this model. Since HDACi decreased the expression of genes required for osteoblast differentiation, we hypothesize that blocking specific stage(s) of osteoblast differentiation may make AML cells within the bone marrow more susceptible to chemotherapy. We are currently disrupting specific osteoblast differentiation stages via molecular or therapeutic drug manipulation and exploring the impact on AML cell survival both in cell culture models of the bone marrow microenvironment and in a mouse model of AML. The results of our studies will characterize novel bone marrow molecular and cellular interactions that promote the survival of AML cells. Targeting these interactions in combination therapies may more completely eradicate the AML cell reservoir and better prevent relapse. Citation Format: Rosalie Sterner, Kimberly Kremer, Amel Dudakovic, Scott Kaufmann, Jennifer Westendorf, Andre van Wijnen, Karen Hedin. Manipulating osteoblast differentiation in order to inhibit protection of AML cells within the bone marrow. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3292.
A Case of Two Repeats: Huntington's Disease and Spinocerebellar Ataxia Type 8
Gass, Jennifer , McKay, Jake H., Guthrie, Kimberly J., Boczek, Nicole J. , Gerpen, Jay Van, Gass, Jennifer M, McKay, Jake, Boczek, Nicole, Atwal, Paldeep S. , Van Gerpen, Jay, Atwal, Paldeep S , Gerpen, Jay A. van

Mayo Clinic

Movement Disorders Clinical Practice | July 23, 2016 | Volume: 4 | Issue: 2 | Pages: 270-272

10.1002/mdc3.12401 | PMID 30838266 Get It

View Supplementary Video 1